Colon Cancer - Pipeline Review, H2 2016

 

Rating

4.8 Star Rating for report Colon Cancer - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 722
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9101IDBLeiomyosarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9094IDBB-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9143IDBMalignant Mesothelioma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9103IDBSynovial Sarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9099IDBRectal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9098IDBAnal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9141IDBHepatic - Colorectal Metastasis - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9138IDBCancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9142IDBHypopharyngeal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9102IDBFibrosarcoma - Pipeline Review, H1 2017Mar 2017

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-30 

Report: Colon Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 8
Colon Cancer Overview 9
Therapeutics Development 10
Colon Cancer - Therapeutics under Development by Companies 12
Colon Cancer - Therapeutics under Investigation by Universities/Institutes 23
Colon Cancer - Pipeline Products Glance 26
Colon Cancer - Products under Development by Companies 29
Colon Cancer - Products under Investigation by Universities/Institutes 42
Colon Cancer - Companies Involved in Therapeutics Development 46
Colon Cancer - Therapeutics Assessment 179
Drug Profiles 203
Colon Cancer - Dormant Projects 660
Colon Cancer - Discontinued Products 680
Colon Cancer - Product Development Milestones 681
Appendix 692
 

List of Tables

List of Tables
Number of Products under Development for Colon Cancer, H2 2016 39
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Development by Companies, H2 2016 (Contd..1) 42
Number of Products under Development by Companies, H2 2016 (Contd..2) 43
Number of Products under Development by Companies, H2 2016 (Contd..3) 44
Number of Products under Development by Companies, H2 2016 (Contd..4) 45
Number of Products under Development by Companies, H2 2016 (Contd..5) 46
Number of Products under Development by Companies, H2 2016 (Contd..6) 47
Number of Products under Development by Companies, H2 2016 (Contd..7) 48
Number of Products under Development by Companies, H2 2016 (Contd..8) 49
Number of Products under Development by Companies, H2 2016 (Contd..9) 50
Number of Products under Development by Companies, H2 2016 (Contd..10) 51
Number of Products under Investigation by Universities/Institutes, H2 2016 52
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54
Comparative Analysis by Late Stage Development, H2 2016 55
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Development, H2 2016 57
Products under Development by Companies, H2 2016 58
Products under Development by Companies, H2 2016 (Contd..1) 59
Products under Development by Companies, H2 2016 (Contd..2) 60
Products under Development by Companies, H2 2016 (Contd..3) 61
Products under Development by Companies, H2 2016 (Contd..4) 62
Products under Development by Companies, H2 2016 (Contd..5) 63
Products under Development by Companies, H2 2016 (Contd..6) 64
Products under Development by Companies, H2 2016 (Contd..7) 65
Products under Development by Companies, H2 2016 (Contd..8) 66
Products under Development by Companies, H2 2016 (Contd..9) 67
Products under Development by Companies, H2 2016 (Contd..10) 68
Products under Development by Companies, H2 2016 (Contd..11) 69
Products under Development by Companies, H2 2016 (Contd..12) 70
Products under Investigation by Universities/Institutes, H2 2016 71
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 72
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 75
Colon Cancer - Pipeline by Adamed Sp z oo, H2 2016 76
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 77
Colon Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 78
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 79
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 80
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 81
Colon Cancer - Pipeline by Affimed GmbH, H2 2016 82
Colon Cancer - Pipeline by Agenus Inc, H2 2016 83
Colon Cancer - Pipeline by AGV Discovery SAS, H2 2016 84
Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 85
Colon Cancer - Pipeline by Almac Discovery Ltd, H2 2016 86
Colon Cancer - Pipeline by Ambrx Inc, H2 2016 87
Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 88
Colon Cancer - Pipeline by AndroScience Corp, H2 2016 89
Colon Cancer - Pipeline by Aphios Corp, H2 2016 90
Colon Cancer - Pipeline by Aposense Ltd, H2 2016 91
Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 92
Colon Cancer - Pipeline by AstraZeneca Plc, H2 2016 93
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 94
Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2016 95
Colon Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 96
Colon Cancer - Pipeline by BioCancell Ltd, H2 2016 97
Colon Cancer - Pipeline by Biogazelle NV, H2 2016 98
Colon Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 99
Colon Cancer - Pipeline by Blirt SA, H2 2016 100
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 101
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 102
Colon Cancer - Pipeline by Celprogen Inc, H2 2016 103
Colon Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 104
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 105
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 106
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2016 107
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2016 108
Colon Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109
Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2016 110
Colon Cancer - Pipeline by Eli Lilly and Company, H2 2016 111
Colon Cancer - Pipeline by EntreChem SL, H2 2016 112
Colon Cancer - Pipeline by EnzymeBioSystems, H2 2016 113
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 114
Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 115
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2016 116
Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2016 117
Colon Cancer - Pipeline by Grunenthal GmbH, H2 2016 118
Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 119
Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2016 120
Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 121
Colon Cancer - Pipeline by Helix BioPharma Corp, H2 2016 122
Colon Cancer - Pipeline by Histogen Inc, H2 2016 123
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2016 124
Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2016 125
Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 126
Colon Cancer - Pipeline by Immunome Inc, H2 2016 127
Colon Cancer - Pipeline by Immunomedics Inc, H2 2016 128
Colon Cancer - Pipeline by Immunotope Inc, H2 2016 129
Colon Cancer - Pipeline by Immupharma Plc, H2 2016 130
Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016 131
Colon Cancer - Pipeline by Incuron LLC, H2 2016 132
Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2016 133
Colon Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 134
Colon Cancer - Pipeline by Innopharmax Inc, H2 2016 135
Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 136
Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 137
Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 138
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 139
Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016 140
Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 141
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 142
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 143
Colon Cancer - Pipeline by Lipocure Ltd, H2 2016 144
Colon Cancer - Pipeline by Lupin Ltd, H2 2016 145
Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2016 146
Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 147
Colon Cancer - Pipeline by MacroGenics Inc, H2 2016 148
Colon Cancer - Pipeline by MaxiVAX SA, H2 2016 149
Colon Cancer - Pipeline by Meabco A/S, H2 2016 150
Colon Cancer - Pipeline by Medicenna Therapeutics Inc, H2 2016 151
Colon Cancer - Pipeline by Microlin Bio, Inc., H2 2016 152
Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2016 153
Colon Cancer - Pipeline by MolMed SpA, H2 2016 154
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2016 155
Colon Cancer - Pipeline by Multimmune GmbH, H2 2016 156
Colon Cancer - Pipeline by NormOxys Inc, H2 2016 157
Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 158
Colon Cancer - Pipeline by Novartis AG, H2 2016 159
Colon Cancer - Pipeline by Omeros Corp, H2 2016 160
Colon Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 161
Colon Cancer - Pipeline by Oncovir Inc, H2 2016 162
Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 163
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2016 164
Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2016 165
Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 166
Colon Cancer - Pipeline by Patrys Ltd, H2 2016 167
Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2016 168
Colon Cancer - Pipeline by Pharminox Ltd, H2 2016 169
Colon Cancer - Pipeline by Philogen SpA, H2 2016 170
Colon Cancer - Pipeline by Pique Therapeutics, H2 2016 171
Colon Cancer - Pipeline by Plexxikon Inc, H2 2016 172
Colon Cancer - Pipeline by ProNAi Therapeutics Inc, H2 2016 173
Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2016 174
Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 175
Colon Cancer - Pipeline by Qu Biologics Inc, H2 2016 176
Colon Cancer - Pipeline by Recce Pty Ltd, H2 2016 177
Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 178
Colon Cancer - Pipeline by Rgenix Inc, H2 2016 179
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2016 180
Colon Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 181
Colon Cancer - Pipeline by Sellas Inc, H2 2016 182
Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2016 183
Colon Cancer - Pipeline by Sirnaomics Inc, H2 2016 184
Colon Cancer - Pipeline by SOM Biotech SL, H2 2016 185
Colon Cancer - Pipeline by Somantix BV, H2 2016 186
Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 187
Colon Cancer - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 188
Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016 189
Colon Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 190
Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2016 191
Colon Cancer - Pipeline by TaiRx Inc, H2 2016 192
Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 193
Colon Cancer - Pipeline by Takis Srl, H2 2016 194
Colon Cancer - Pipeline by Targovax ASA, H2 2016 195
Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 196
Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2016 197
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2016 198
Colon Cancer - Pipeline by TyrNovo Ltd, H2 2016 199
Colon Cancer - Pipeline by Vaccinogen Inc, H2 2016 200
Colon Cancer - Pipeline by Vault Pharma Inc, H2 2016 201
Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2016 202
Colon Cancer - Pipeline by Vaximm AG, H2 2016 203
Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2016 204
Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2016 205
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 206
Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016 207
Assessment by Monotherapy Products, H2 2016 208
Assessment by Combination Products, H2 2016 209
Number of Products by Stage and Target, H2 2016 211
Number of Products by Stage and Mechanism of Action, H2 2016 220
Number of Products by Stage and Route of Administration, H2 2016 229
Number of Products by Stage and Molecule Type, H2 2016 231
Colon Cancer - Dormant Projects, H2 2016 689
Colon Cancer - Dormant Projects (Contd..1), H2 2016 690
Colon Cancer - Dormant Projects (Contd..2), H2 2016 691
Colon Cancer - Dormant Projects (Contd..3), H2 2016 692
Colon Cancer - Dormant Projects (Contd..4), H2 2016 693
Colon Cancer - Dormant Projects (Contd..5), H2 2016 694
Colon Cancer - Dormant Projects (Contd..6), H2 2016 695
Colon Cancer - Dormant Projects (Contd..7), H2 2016 696
Colon Cancer - Dormant Projects (Contd..8), H2 2016 697
Colon Cancer - Dormant Projects (Contd..9), H2 2016 698
Colon Cancer - Dormant Projects (Contd..10), H2 2016 699
Colon Cancer - Dormant Projects (Contd..11), H2 2016 700
Colon Cancer - Dormant Projects (Contd..12), H2 2016 701
Colon Cancer - Dormant Projects (Contd..13), H2 2016 702
Colon Cancer - Dormant Projects (Contd..14), H2 2016 703
Colon Cancer - Dormant Projects (Contd..15), H2 2016 704
Colon Cancer - Dormant Projects (Contd..16), H2 2016 705
Colon Cancer - Dormant Projects (Contd..17), H2 2016 706
Colon Cancer - Dormant Projects (Contd..18), H2 2016 707
Colon Cancer - Dormant Projects (Contd..19), H2 2016 708
Colon Cancer - Discontinued Products, H2 2016 709
 

List of Figures

List of Figures
Number of Products under Development for Colon Cancer, H2 2016 39
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Investigation by Universities/Institutes, H2 2016 52
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Products, H2 2016 57
Assessment by Monotherapy Products, H2 2016 208
Assessment by Combination Products, H2 2016 209
Number of Products by Top 10 Targets, H2 2016 210
Number of Products by Stage and Top 10 Targets, H2 2016 210
Number of Products by Top 10 Mechanism of Actions, H2 2016 219
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 219
Number of Products by Top 10 Routes of Administration, H2 2016 228
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228
Number of Products by Top 10 Molecule Types, H2 2016 230
Number of Products by Stage and Top 10 Molecule Types, H2 2016 230
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 722 

Companies Featured

Actinium Pharmaceuticals Inc Adamed Sp z oo Adgero Biopharmaceuticals Inc Advanced Cancer Therapeutics Advanced Proteome Therapeutics Corp Advenchen Laboratories LLC Aeglea BioTherapeutics Inc Affimed GmbH Agenus Inc AGV Discovery SAS AIMM Therapeutics BV Almac Discovery Ltd Ambrx Inc Anavex Life Sciences Corp AndroScience Corp Aphios Corp Aposense Ltd Aptose Biosciences Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd BCN Biosciences LLC Bio-Path Holdings Inc BioCancell Ltd Biogazelle NV Bioncotech Therapeutics SL Blirt SA Boehringer Ingelheim GmbH Can-Fite BioPharma Ltd Celprogen Inc Chiome Bioscience Inc Cyclacel Pharmaceuticals Inc CytomX Therapeutics Inc Cytune Pharma SAS CZ BioMed Corp Daiichi Sankyo Company Ltd DEKK-TEC Inc Eli Lilly and Company EntreChem SL EnzymeBioSystems F. Hoffmann-La Roche Ltd GlaxoSmithKline Plc GlycaNova Norway AS GlycoMimetics Inc Grunenthal GmbH Halozyme Therapeutics Inc Hamlet Pharma AB Hanmi Pharmaceuticals Co Ltd Helix BioPharma Corp Histogen Inc Horizon Pharma Plc Idera Pharmaceuticals Inc Immune Pharmaceuticals Inc Immunome Inc Immunomedics Inc Immunotope Inc Immupharma Plc IMPACT Therapeutics Inc Incuron LLC Infinity Pharmaceuticals Inc Inflection Biosciences Ltd Innopharmax Inc Intezyne Technologies Inc Ironwood Pharmaceuticals Inc Jasco Pharmaceuticals LLC Jiangsu Kanion Pharmaceutical Co Ltd JW Pharmaceutical Corp Karyopharm Therapeutics Inc Kyowa Hakko Kirin Co Ltd Les Laboratoires Servier SAS Lipocure Ltd Lupin Ltd Lymphocyte Activation Technologies SA MabVax Therapeutics Holdings Inc MacroGenics Inc MaxiVAX SA Meabco A/S Medicenna Therapeutics Inc Microlin Bio, Inc. Molecular Targeting Technologies Inc MolMed SpA Monopar Therapeutics LLC Multimmune GmbH NormOxys Inc Northwest Biotherapeutics Inc Novartis AG Omeros Corp Omnitura Therapeutics Inc Oncovir Inc Ono Pharmaceutical Co Ltd Orega Biotech SAS OSE Immunotherapeutics Panacea Pharmaceuticals Inc Patrys Ltd PharmaCyte Biotech Inc Pharminox Ltd Philogen SpA Pique Therapeutics Plexxikon Inc ProNAi Therapeutics Inc Provecs Medical GmbH Provectus Biopharmaceuticals Inc Qu Biologics Inc Recce Pty Ltd Rexahn Pharmaceuticals Inc Rgenix Inc Sareum Holdings Plc Savoy Pharmaceuticals Inc Sellas Inc Sigma-Tau SpA Sirnaomics Inc SOM Biotech SL Somantix BV Sorrento Therapeutics Inc Sphaera Pharma Pvt Ltd Starpharma Holdings Ltd Sunshine Biopharma Inc Synergys Biotherapeutics Inc TaiRx Inc Taiwan Liposome Company Ltd Takis Srl Targovax ASA Transgene Biotek Ltd TVAX Biomedical Inc Tyg Oncology Ltd TyrNovo Ltd Vaccinogen Inc Vault Pharma Inc Vaxenta Biotechnologies Vaximm AG VG Life Sciences Inc Yakult Honsha Co Ltd Zensun (Shanghai) Sci & Tech Co Ltd ZIOPHARM Oncology Inc

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9101IDBLeiomyosarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9094IDBB-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9143IDBMalignant Mesothelioma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9103IDBSynovial Sarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9099IDBRectal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9098IDBAnal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9141IDBHepatic - Colorectal Metastasis - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9138IDBCancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9142IDBHypopharyngeal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9102IDBFibrosarcoma - Pipeline Review, H1 2017Mar 2017

Colon Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8848IDB has a rating of 96.6 percent
Figure of merit assessment for report 05IB-GMDHC8848IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Colon Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8848IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [2.91015s]

--